Image: Stereotaxis
July 9, 2026 — On July 9, Stereotaxis announced that it has completed its previously announced acquisition of Robocath, a provider of robotic technologies for interventional cardiology and neurointerventions.
Robocath will now be fully integrated into Stereotaxis, combining complementary technologies and expertise to accelerate the development of next-generation robotic solutions for electrophysiology, interventional cardiology and neurointerventions. The combined platform strengthens Stereotaxis’s position as the leader in robotic technologies across the full spectrum of endovascular procedures.
“We’re very excited to join Stereotaxis,” said Philippe Bencteux, Robocath founder and CEO. “Combining the strengths, expertise, and technologies of two pioneers in endovascular robotics, we now have the opportunity to accelerate innovation, expand our global reach, and bring robotic solutions to many more physicians and patients around the world.”
“The addition of Robocath’s technology and team to Stereotaxis accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies in an expanded addressable market, and supports new strategic opportunities,” said David Fischel, Stereotaxis Chairman and CEO.
June 22, 2026 
